Soleno Therapeutics, Inc. (FRA:6XC)

Soleno Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-78.45	-175.85	-38.99	-24.07	-30.91	-24.64
Depreciation & Amortization	2.01	1.99	1.96	1.96	1.96	1.95
Loss (Gain) From Sale of Investments	-3.73	-4.9	-	-	-	-
Stock-Based Compensation	64.13	99.96	5.95	2.53	3.28	1.5
Other Operating Activities	5.72	3.69	3.22	-0.45	-0.95	-7.01
Change in Accounts Receivable	-25.51	-	-	-	-	-
Change in Inventory	-6.01	-	-	-	-	-
Change in Accounts Payable	1.9	5.67	1.37	-1.48	-0.24	1.49
Change in Other Net Operating Assets	14	0.35	1.56	0.72	-0.91	1.48
Operating Cash Flow	-25.9	-69.1	-24.94	-20.78	-27.77	-25.22
Capital Expenditures	-0.02	-0.22	-	-0.01	-0.02	-0.01
Investment in Securities	-69.96	-225.46	-	-	-	-
Investing Cash Flow	-69.98	-225.68	-	-0.01	-0.02	-0.01
Long-Term Debt Issued	-	49.89	-	-	-	-
Total Debt Issued	49.89	49.89	-	-	-	-
Long-Term Debt Repaid	-	-	-	-	-0.01	-0.02
Total Debt Repaid	-	-	-	-	-0.01	-0.02
Net Debt Issued (Repaid)	49.89	49.89	-	-	-0.01	-0.02
Issuance of Common Stock	244.33	163.14	180.02	14.11	-	53.74
Repurchase of Common Stock	-0.03	-	-	-0.02	-0.12	-
Other Financing Activities	-0.06	-	-	-	-	-
Financing Cash Flow	294.12	213.03	180.02	14.09	-0.13	53.72
Net Cash Flow	198.25	-81.75	155.08	-6.7	-27.92	28.49
Free Cash Flow	-25.92	-69.31	-24.94	-20.79	-27.79	-25.23
Free Cash Flow Per Share	-0.53	-1.73	-1.51	-2.48	-5.23	-6.04
Levered Free Cash Flow	-5.7	-7.47	-12.82	-11.71	-15.79	-13.3
Unlevered Free Cash Flow	-3	-7.33	-12.82	-11.71	-15.79	-13.3
Change in Working Capital	-15.61	6.02	2.93	-0.76	-1.15	2.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.